Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

LESSONS LEARNED. Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status. Whether this combination is superior to tem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Reyes‐Botero, Germán, Cartalat‐Carel, Stéphanie, Chinot, Olivier L., Barrie, Maryline, Taillandier, Luc, Beauchesne, Patrick, Catry‐Thomas, Isabelle, Barrière, Jérôme, Guillamo, Jean‐Sebastien, Fabbro, Michel, Frappaz, Didier, Benouaich‐Amiel, Alexandra, Le Rhun, Emilie, Campello, Chantal, Tennevet, Isabelle, Ghiringhelli, François, Tanguy, Marie‐Laure, Mokhtari, Karima, Honnorat, Jérôme, Delattre, Jean‐Yves
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947454/
https://ncbi.nlm.nih.gov/pubmed/29472310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados